Drug intelligence / Profile preview

MEVAC Coryza

Development stage: Unknown
Lead developer: MEVAC
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

MEVAC Coryza is an inactivated bacterial vaccine (biologic) developed by Middle East for Vaccines (MEVAC) to protect poultry against infectious coryza, a respiratory disease caused by the bacterium *Avibacterium paragallinarum*. The vaccine is designed to induce a protective immune response against multiple serotypes of the pathogen, typically including serotypes A, B, and C. Infectious coryza is characterized by respiratory symptoms such as nasal discharge and facial swelling, and it can lead to significant economic losses in poultry farming due to a 10-40% decrease in egg production in laying hens.

Brand names: MEVAC Coryza
Other names: Coryza VaccineInfectious Coryza Vaccine

Beyond the preview

Go deeper on MEVAC Coryza.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEVAC Coryza.

Explore the full profile